"Each client is unique and requires an individual approach. Guided by this philosophy, our specialists develop intelligent and 100% efficient multidisciplinary programs in preclinical drug research and chemical safety evaluation"
QT shift and probabilistic method: powerful approaches for detection of QT prolongation in a most reliable manner. >>>
TDPscreen: a tool invented by CERB for characterization of torsadogenic profiles
>>>
Founded in 1973, CERB has developed to a leading international contract research organization (CRO) in the fields of preclinical pharmacology and toxicology. Taking on the challenges of modern drug development CERB has created its distinctive image of a major service provider to the pharmaceutical industry in the context of innovative biomedical research.
Our toxicology department has also proven to be a valuable partner to other branches, such as chemical and agro-chemical industries, in the field of regulatory safety assessment.
.
For the pharmaceutical industry, CERB takes advantage of its sophisticated synergy between pharmacology and toxicology resources to provide complete pre-phase I packages for a new molecule in an economic and timely manner. Having developed/validated more than 100 models and techniques in pharmacology we take on any challenge of specialized approaches fitting the requirements of your compound. A fully equipped chemical analysis unit assures back-up support for drug quantification in chemical or biological matrices as well as biomarker verification.
Our main assets are:
- high quality of scientific and administrative performance
- continuous innovation through targeted scientific input
- a network of independent, internationally renowned experts and cooperations
- the dedication to provide custom-made answers
- reactivity and flexibility
Last publication: "Interferences of the autonomic nervous system with drug induced QT prolongation: a point to consider in non-clinical safety studies" >>>
NEW: partnership with GENOSAFE for biodistribution studies requested in safety studies of gene transfer vectors >>>
NEW: partnership with Dr. Vierling Consult for preparation of preclincal documentation (e.g. CTD-Modules 2.4 and 2.6)
>>>